Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Braveheart Bio, Inc. (BRVE)

Braveheart Bio Q2 net loss widens to $15.0 million from $0.4 million a year earlier

Negative Impact 3 of 5 earnings Written later

Braveheart Bio, a clinical-stage company with no reported revenue, posted a second-quarter 2026 net loss of $15.0 million, up from $0.4 million a year earlier, as R&D and G&A spending rose. Cash was $122.8 million at June 30, 2026, or about $527.3 million on an as-adjusted basis after its August 2026 IPO, which the company says funds operations into 2029.

Key points

  • Net loss attributable to common stockholders was $18.6 million, or $2.51 per share, versus $0.14 per share in Q2 2025; this includes a $3.6 million non-cash deemed dividend.
  • R&D expenses were $11.1 million and G&A expenses were $4.8 million for the quarter, compared with $0.0 million and less than $0.1 million a year earlier.
  • Cash and cash equivalents were $122.8 million at June 30, 2026; the IPO closed in August 2026 with aggregate net proceeds of about $404.5 million.
  • The company said the first patient in the LIONHEART-HCM Phase 3 trial is expected to be dosed this year, and the NOBLEHEART-HCM Phase 3 trial is expected to start in the first half of 2027.

The filing

CompanyBraveheart Bio, Inc. (BRVE)
Form8-K, current report
Filed with the SECSep 8, 2026, 4:06 PM ET
Accession number0001628280-26-060904

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.